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Abstract
JC virus has a transforming gene encoding JC virus T-antigen (JCVT). JCVT may inactivate wild-type p53, cause
chromosomal instability (CIN), and stabilize β-catenin. A link between JCVT and CpG island methylator phenotype
(CIMP) has been suggested. However, no large-scale study has examined the relations of JCVT with molecular
alterations, clinical outcome, or prognosis in colon cancer. We detected JCVT expression (by immunohistochem-
istry) in 271 (35%) of 766 colorectal cancers. We quantified DNA methylation in eight CIMP-specific promoters
(CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) and eight other loci (CHFR, HIC1,
IGFBP3, MGMT, MINT1, MINT31, p14, WRN) by MethyLight. We examined loss of heterozygosity in 2p,
5q, 17q, and 18q. JCVT was significantly associated with p53 expression (P < .0001), p21 loss (P < .0001), CIN
(≥2 chromosomal segments with LOH; P < .0001), nuclear β-catenin (P = .006), LINE-1 hypomethylation (P =
.002), and inversely with CIMP-high (P = .0005) and microsatellite instability (MSI) (P < .0001), but not with PIK3CA
mutation. In multivariate logistic regression analysis, the associations of JCVT with p53 [adjusted odds ratio (OR),
8.45; P < .0001], CIN (adjusted OR, 2.53; P = .003), cyclin D1 (adjusted OR, 1.57; P = .02), LINE-1 hypomethylation
(adjusted OR, 1.97 for a 30% decline as a unit; P = .03), BRAF mutation (adjusted OR, 2.20; P = .04), and family
history of colorectal cancer (adjusted OR, 0.64; P = .04) remained statistically significant. However, JCVT was no
longer significantly associated with CIMP, MSI, β-catenin, or cyclooxygenase-2 expression in multivariate analysis.
JCVT was unrelated with patient survival. In conclusion, JCVT expression in colorectal cancer is independently asso-
ciated with p53 expression and CIN, which may lead to uncontrolled cell proliferation.
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Introduction
The Polyomavirus family includes the simian virus 40 (SV40), JC
virus, and BK virus. JC virus is a 5.12-kb, double-stranded, circular,
negatively supercoiled DNA virus that commonly infects human
cells [1,2]. It has a transforming gene encoding JC virus T-antigen
(JCVT), which is believed to mediate the oncogenic potential of
the virus [1–10]. Previous studies have suggested the link between
JCVT and various human cancers [1,3–9,11,12], including colon
cancers [5–7,9,12]. JC virus T-antigen has been reported to bind
and inactivate wild type p53 [5,11] and cause chromosomal instabil-
ity (CIN) [5–7], as well as the stabilization of β-catenin [8,9]. In ad-
dition, a previous study has suggested a link between JCVT and
promoter methylation leading to the CpG island methylator pheno-
type (CIMP) in colorectal cancer [6].
CpG island methylator phenotype is characterized by a wide-
spread, concordant CpG island methylation pattern [13–16]. CpG
island methylator phenotype–high in colorectal cancer has been as-
sociated with older age, female sex, proximal tumor location, BRAF
mutation, microsatellite instability (MSI), wild type TP53, inactive
WNT/β-catenin, high-level long interspersed nucleotide element 1
(LINE-1) methylation, and stable chromosomes [17–30]. However,
to our knowledge, no large-scale study has been conducted to exam-
ine the relationship of JCVT with genetic/epigenetic alterations or
clinical outcome in colorectal cancer.
In this study, using a large number (n = 766) of stage I to IV
colorectal cancers in two independent cohort studies, we examined
tumoral JCVT expression in relation to clinical, pathologic, and mo-
lecular features in colorectal cancers. We have found that JCVT ex-
pression is significantly associated with p53 expression and CIN but
not independently with CIMP or patient survival.
Materials and Methods
Study Group
We used the databases of two large prospective cohort studies;
the Nurses’ Health Study (n = 121,700 women observed since
1976) [31,32], and the Health Professional Follow-up Study (n =
51,500 men observed since 1986) [32]. Data on height and weight
were obtained by biennial questionnaire. A subset of the cohort par-
ticipants developed colorectal cancers during prospective follow-up.
Previous studies on the Nurses’ Health Study and Health Profes-
sionals Follow-up Study have described baseline characteristics of
cohort participants and incident colorectal cancer cases and con-
firmed that our colorectal cancers were a good representative as a
population-based sample [31,32]. Data on tumor location and stage
were obtained through medical record review. We collected paraffin-
embedded tissue blocks from hospitals where cohort participants
with colorectal cancers had undergone resections of primary tumors.
On the basis of availability of adequate tissue specimens and results, a
total of 766 colorectal cancers were included. Written informed con-
sent was obtained from all study subjects. Among our cohort studies,
there was no significant difference in the demographic features be-
tween cases with tissue available and those without available tissue
[32]. This current analysis represents a new analysis of JCVT on
the existing colorectal cancer database that have been previously char-
acterized for CIMP, MSI, p53, KRAS, or BRAF [33], which is anal-
ogous to novel studies using the well-described cell lines or animal
models. In any of our previous studies, we have not examined JCVT
expression or the relations between JCVT and other molecular
events. This study represents a unique novel study about the follow-
ing: 1) a large sample size analyzed for JCVT; 2) the validated set of
CIMP-specific methylation markers; and 3) a number of other mo-
lecular events analyzed, including eight CpG islands other than the
CIMP-specific markers, MSI, CIN, KRAS, BRAF, PIK3CA, p53,
LINE-1 methylation, cyclin D1, p21, cyclooxygenase 2 (COX-2),
and β-catenin. Tissue collection and analyses were approved by the
Harvard School of Public Health and Brigham and Women’s Hospi-
tal Institutional Review Boards.
Histopathologic Evaluations
Hematoxylin and eosin–stained tissue sections were examined by
a pathologist (S.O.) unaware of other data. The tumor grade was
categorized as low (≥50% gland formation) or high (<50% gland
formation). The presence and extent of extracellular mucin were cat-
egorized as 0% (no mucin) or ≥1% of the tumor volume. The pres-
ence and extent of signet ring cells were categorized as 0% (no signet
ring cells) or ≥1% of the tumor volume.
Sequencing of KRAS, BRAF, and PIK3CA and Analyses for
MSI and LOH
Genomic DNA was extracted from dissected tumor tissue sections,
and whole-genome amplification was performed by polymerase
chain reaction (PCR) using random 15-mer primers [34]. Polymerase
chain reaction and Pyrosequencing targeted for KRAS (codons 12
and 13), BRAF (codon 600), and PIK3CA (exons 9 and 20) were
performed as previously described [34]. Microsatellite instability
analysis was performed, using 10 microsatellite markers (D2S123,
D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56,
D18S67, and D18S487) [33]. Microsatellite instability–high was de-
fined as the presence of instability in ≥30% of the markers. Micro-
satellite instability–low was defined as instability in <30% of the
markers, and microsatellite stable (MSS) tumors were defined as tu-
mors without an unstable marker.
For loss of heterozygosity (LOH) analysis using microsatellite
markers (D2S123, D5S346, D17S250, D18S55, D18S56, D18S67,
and D18S487), we duplicated the PCR in each sample to exclude allele
dropouts of one of two alleles. Loss of heterozygosity at each locus was
defined as ≥40% reduction of one of two allele peaks in tumor DNA
relative to normal DNA. We obtained informative CIN results in 514
tumors (67%). The overall CIN score was defined as the number of
chromosomal segments (among 2p, 5q, 17q, and 18q) that were positive
for LOH.
Real-time PCR (MethyLight) for Quantitative DNA
Methylation Analysis
Sodium bisulfite treatment on genomic DNA and subsequent
real-time PCR (MethyLight) [35] were validated and performed as
previously described [36]. We quantified DNA methylation in eight
CIMP-specific promoters [CACNA1G, CDKN2A (p16), CRABP1,
IGF2, MLH1, NEUROG1, RUNX3, and SOCS1] [24,33], all of
which were selected from screening of 195 CpG islands [24,33].
CpG island methylator phenotype–high was defined as the presence
of ≥6 of 8 methylated promoters, CIMP-low as the presence of 1/8
to 5/8 methylated promoters, and CIMP-0 as the absence (0/8) of
methylated promoters, according to the previously established criteria
[33]. In addition, we quantified DNA methylation in eight other
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CpG islands (not in the CIMP panel), including CHFR, HIC1,
IGFBP3, MGMT, MINT1, MINT31, p14, and WRN. Primers and
probes were previously described [24], except for HIC1, IGFBP3,
p14, and WRN: HIC1-F, 5′-TTC GTT ACG GTA GTC GTT
GTT TTC-3′ (GenBank no. L41919, nucleotide nos. 43-66); HIC1-R,
5′-GAA AAC TAT CAA CCC TCG ATC GA-3′ (nucleotide nos. 94-
116); HIC1-probe, 6FAM-5′-TCG CGC GGT CGT CGT TCG-
3′ -BHQ-1 (nucleotide nos. 72-89); IGFBP3-F, 5′-GTT TCGGGC
GTGAGT ACGA-3′ (GenBank no.M35878, nucleotide nos. 1692-
1710); IGFBP3-R, 5′-GAA TCG ACG CAA ACA CGA CTA
C-3′ (nucleotide nos. 1789-1810) and IGFBP3-probe, 6FAM-TCG
GT T GTT TAG GGC GAA GTA CGG G-BHQ-1 (nucleotide
nos. 1760-1784; bisulfite-converted nucleotides are highlighted by
bold face and italics); P14 (CDKN2A/ARF)-F, 5′-TTG GAG GCG
GCG AGA ATA T-3′ (GenBank no. L41934, nucleotide nos. 238-
256); P14-R, 5′-CCC CGT AAA CCG CGA AAT A-3′ (nucleotide
nos. 332-350); P14-probe, 6FAM-5′-CGG TTC GTC GCG AGT
GAG GGT T-3′ -BHQ-1 (nucleotide nos. 299-320); WRN-F, 5′-
GTA TCG TTC GCG GCG TTT AT-3′ (GenBank no. AY442327,
nucleotide nos. 1827-1846); WRN-R, 5′-ACG AAA CCG ATA TCC
GAA ATC A -3′ (nucleotide nos. 1887-1908) and WRN-probe,
6FAM-TTT TTT TTGCGG TCG TTG CGGG-BHQ-1 (nucleo-
tide nos. 1855-1876). The PCR condition for all markers was initial
denaturation at 95°C for 10 minutes followed by 45 cycles at 95°C
for 15 seconds and 60°C for 1 minute [37].
Pyrosequencing to Measure LINE-1 Methylation
To accurately quantify relatively high methylation levels in LINE-1
repetitive elements, we used Pyrosequencing as previously described
[29]. The LINE-1 methylation level measured by Pyrosequencing
has been shown to correlate well with overall 5-methylcytosine level
(i.e., genome-wide DNA methylation level) in tumor cells [38,39].
Immunohistochemistry for p53, p21, β-catenin, COX2,
Cyclin D1, and JCVT
Tissue microarrays (TMAs) were constructed as previously de-
scribed [32]. Methods of immunohistochemical procedures and in-
terpretations were previously described for p53 [40], p21 (CDKN1A)
[41,42], β-catenin [25], COX-2 [32], and cyclin D1 [43].
For JCVT, antigen retrieval was performed, and deparaffinized tis-
sue sections in Antigen Retrieval Citra Solution (Biogenex Laborato-
ries, San Ramon, CA) were treated with microwave in a pressure
cooker for 20 minutes. Tissue sections were incubated with 3%
H2O2 (10 minutes) to block endogenous peroxidase (Dako Cytoma-
tion, Carpinteria, CA). Primary antibody against JCVT [mouse
monoclonal anti-SV40 Tantigen (clone PAb416), 1:60 dilution; On-
cogene Research Products, San Diego, CA] was applied, and the
slides were maintained overnight at room temperature. Next, we ap-
plied an antimouse IgG antibody (Vector Laboratories, Burlingame,
CA) for 30 minutes, followed by an avidin-biotin complex conjugate
(Vector Laboratories) for 30 minutes, diaminobenzidine (5 minutes)
and methyl-green counterstain. Nuclear JCVT expression was re-
corded as no expression, weak expression, or moderate/strong expres-
sion (Figure 1). JC virus T-antigen positivity (i.e., expression) was
Figure 1. JC virus T-antigen expression in colorectal cancer. (A) No
overexpression of JCVT in cancer cells (arrows). (B) Overexpres-
sion of JCVT in nuclei of cancer cells (block arrows).
Table 1. Frequency of JCVT Expression in Colorectal Cancer.
Clinical or Pathologic Feature Total N JCVT+ Univariate OR (95% CI) P
All cases 766 271 (35%)
Sex
Men 334 117 (35%) 1
Women 432 154 (36%) 1.03 (0.76-1.39)
Age, years
≤59 174 60 (34%) 1
60-69 328 106 (32%) 0.91 (0.61-1.34)
≥70 264 105 (40%) 1.25 (0.84-1.87)
BMI, kg/m2
<25 301 106 (35%) 1
25-30 301 107 (36%) 1.01 (0.73-1.42)
≥30 130 44 (34%) 0.94 (0.61-1.45)
Family history of colorectal cancer
(−) 580 216 (37%) 1
(+) 186 55 (30%) 0.71 (0.50-1.01)
Tumor location
Distal (splenic flexure to rectum) 429 173 (40%) 1 Referent
Proximal (cecum to transverse) 328 96 (29%) 0.61 (0.45-0.83) .002
Stage
I-II 289 139 (36%) 1
III 203 83 (41%) 1.24 (0.88-1.76)
IV 103 32 (31%) 0.81 (0.51-1.29)
Tumor grade
Low 653 247 (38%) 1 Referent
High 57 14 (25%) 0.54 (0.29-1.00) .046
Mucinous component
0% 523 207 (40%) 1 Referent
≥1% 243 64 (26%) 0.55 (0.39-0.76) .0004
Signet ring cell component
0% 719 256 (36%) 1
≥1% 47 15 (32%) 0.85 (0.45-1.60)
Only significant P values are described.
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defined as the presence of at least weak nuclear staining. Appro-
priate positive and negative controls were included in each run of
immunohistochemistry. All immunohistochemically stained slides
were interpreted by one of the investigators (JCVT, cyclin D1, and
β-catenin by K.N.; p53, p21, and COX-2 by S.O.) unaware of other
data. A random selection of 147 cases was examined for JCVT by a
second observer (Y.B.) unaware of other data, and concordance be-
tween the two observers was 0.87 (κ = 0.74, P < .0001), indicating
substantial agreement.
Statistical Analysis
All statistical analyses used SAS program (Version 9.1; SAS Insti-
tute, Cary, NC). All P values were two-sided, and statistical signifi-
cance was set at P ≤ .05; however, P values were conservatively
interpreted, considering multiple hypotheses testing. For categorical
data, the χ 2 test (or Fisher exact test when any expected cell count
was less than 5) was performed and odds ratio (OR) with 95% con-
fidence interval (CI) was computed. To compare mean LINE-1
methylation levels, the t test assuming unequal variances was per-
formed. The κ coefficient was calculated to assess an agreement
between the two interpreters in immunohistochemistry. To assess
independent relations of JCVTwith a number of variables, a multi-
variate logistic regression analysis was performed. Odds ratio was ad-
justed for age (<65 vs ≥65 years), sex, tumor location (proximal vs
distal), body mass index (BMI, ≥30 vs <30 kg/m2), tumor stage (I-II
vs III-IV), grade (low vs high), family history (present vs absent), mucin
(present vs absent), signet ring cells (present vs absent), CIMP status
(high vs low/0), MSI status (high vs low/MSS), LINE-1 methylation
Table 2. Frequency of JCVT Expression in Colorectal Cancer According to Various Molecular Features.
Molecular Feature Total N JCVT+ Univariate OR (95% CI) P
CIMP status (no. of methylated CIMP markers)
CIMP-0 (0) 335 127 (38%) 1 Referent
CIMP-low (1-5) 277 115 (42%) 1.16 (0.84-1.61)
CIMP-high (6-8) 107 21 (20%) 0.40 (0.24-0.68) .0005
MSI Status
MSS 583 236 (40%) 1 Referent
MSI-low 51 18 (35%) 0.80 (0.44-1.46)
MSI-high 104 15 (14%) 0.25 (0.14-0.44) <.0001
CIMP-low/0 MSI-low/MSS 573 238 (42%) 1 Referent
CIMP-high MSI-low/MSS 37 11 (30%) 0.60 (0.29-1.23)
CIMP-low/0 MSI-high 31 4 (13%) 0.21 (0.07-0.60) .002
CIMP-high MSI-high 70 10 (14%) 0.23 (0.12-0.47) <.0001
BRAF mutation
(−) 631 233 (37%) 1
(+) 95 31 (33%) 0.83 (0.52-1.31)
KRAS mutation
(−) 470 170 (36%) 1
(+) 276 98 (36%) 0.97 (0.71-1.32)
PIK3CA mutation
(−) 564 208 (37%) 1
(+) 102 35 (34%) 0.89 (0.57-1.39)
LINE-1 methylation
≥70% 43 6 (14%) 1 Referent
60-70% 362 136 (38%) 3.71 (1.53-9.02) .002
50-60% 271 105 (39%) 3.90 (1.59-9.56) .002
<50% 31 13 (41%) 4.45 (1.45-13.6) .007
CIN score*
0 139 37 (27%) 1 Referent
1+ 241 241 (37%) 1.59 (1.00-2.51) .048
≥2+ 134 70 (52%) 3.02 (1.82-5.00) <.0001
p53 expression
(−) 422 69 (16%) 1 Referent
(+) 331 201 (61%) 7.91 (5.63-11.1) <.0001
p21
Expressed 130 27 (21%) 1 Referent
Lost 595 234 (39%) 2.47 (1.57-3.90) <.0001
Cyclin D1 expression
(−) 342 127 (37%) 1
(+) 378 139 (37%) 0.98 (0.72-1.33)
Nuclear β-catenin
(−) 431 142 (33%) 1 Referent
(+) 241 105 (44%) 1.57 (1.14-2.17) .006
COX-2 expression
(−) 116 30 (26%) 1 Referent
(+) 645 241 (37%) 1.71 (1.10-2.67) .02
Only significant P values are described.
*The CIN score was defined as the number of chromosomal segments (among 2p, 5q, 17q, and 18q) positive for LOH.
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(as a continuous variable), β-catenin, COX-2, cyclin D1, p53, p21,
BRAF, KRAS, and PIK3CA.
For survival analysis, Kaplan-Meier analysis was performed to
assess survival time distributions according to JCVT status, and log-
rank test was performed. We also constructed a multivariate, stage-
matched conditional Cox proportional hazard model to compute
hazard ratios (HRs) according to tumoral JCVT status, adjusted for
age, sex, year of diagnosis, tumor location, stage, grade, CIMP, MSI,
KRAS, BRAF, PIK3CA, β-catenin, COX-2, cyclin D1 p53, p21, and
LINE-1 methylation. In addition, a univariate Cox proportional haz-
ard model was used to assess the main effect of JCVTon patient mor-
tality. For the analyses of colorectal cancer-specific mortality, death
because of colorectal cancer was the primary end point and deaths be-
cause of other causes were censored. The proportionality of hazards
assumption was satisfied by evaluating time-dependent variables,
which were the cross product of the JCVT variable and survival time
(P = .30 for colon cancer-specific mortality; P = .48 for overall mor-
tality). To adjust for potential confounding, age, year of diagnosis, and
LINE-1 methylation were used as continuous variables, and all of the
other covariates were used as categorical variables. An interaction was
assessed by including the cross product of the JCVT variable and an-
other variable of interest in a multivariate Cox model, and the likeli-
hood ratio test was performed.
Results
JC Virus T-Antigen Expression in Colorectal Cancers
Among the 766 colorectal cancers assessed by immunohistochem-
istry, 271 (35%) tumors overexpressed JCVT. Table 1 summarizes
the frequencies of JCVT expression according to various clinical
and pathologic features. JC virus T-antigen expression was inversely
associated with proximal location (P = .002), high grade (P = .046),
and mucinous component (P = .0004).
Relationship of JCVT with CIMP and MSI Status
We determined CIMP status using MethyLight assays on a panel
of eight CIMP-specific promoters (CACNA1G, CDKN2A, CRABP1,
IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) [24,33]. Table 2
summarizes the frequencies of JCVT expression according to CIMP
and other molecular features in colorectal cancer. JC virus T-antigen
expression was inversely associated with CIMP-high (≥6/8 methylated
promoters; OR, 0.40; 95% CI, 0.24-0.68, compared to CIMP-0;
P = .0005) and MSI-high (OR, 0.25; 95% CI, 0.14-0.44, compared
to MSS; P < .0001). To examine the combined effect of MSI and
CIMP on JCVT expression, we classified tumors into four subtypes
according to CIMP and MSI status (Table 2). JC virus T-antigen
overexpression was significantly less common in CIMP-high MSI-
high [14% (10/70), P < .0001) and CIMP-low/0 MSI-high [13%
(4/31), P = .002] than in CIMP-low/0 MSI-low/MSS tumors
[42% (238/573)].
JC Virus T-Antigen and Other Molecular Changes
We determined the CIN score in MSS/MSI-low tumors as the
number of chromosomal segments (among 2p, 5q, 17q, and 18q)
positive for LOH. JC virus T-antigen was significantly associated
with high CIN score (≥2+; OR, 3.02; 95% CI, 1.82-5.00, compared
to CIN score 0; P < .0001; Table 2). JC virus T-antigen expression
was also significantly associated with p53 expression (P < .0001), loss
of p21 expression (P < .0001), nuclear β-catenin expression (P =
.006), and COX-2 expression (P = .02). In contrast, JCVTexpression
was not significantly associated with alterations in KRAS, BRAF,
PIK3CA, or cyclin D1.
JC Virus T-Antigen and Methylation in Individual
CpG Islands
Because JCVT has been implicated in CpG island methylation
[6], we examined the relationship of JCVT with methylation in 16
individual CpG islands, including the 8 CIMP-specific promoters
(Table 3). In the univariate analysis, JCVT was inversely associated
Table 3. Frequency of JCVT in Colorectal Cancer According to Methylation Marker Status.
Methylation Marker Total N JCVT+ Univariate OR
(95% CI)
OR Adjusted for
CIMP (95% CI)
P
CIMP marker panel*
CACNA1G*
(−) 564 221 (39%) 1 1
(+) 155 42 (27%) 0.58 (0.39-0.85) 1.13 (0.64-2.00)
CDKN2A (p16)*
(−) 506 186 (37%) 1 1 Referent
(+) 213 77 (36%) 0.97 (0.70-1.36) 1.63 (1.09-2.42) .016
CRABP1*
(−) 492 192 (39%) 1 1
(+) 227 71 (31%) 0.71 (0.51-0.99) 1.11 (0.74-1.65)
IGF2*
(−) 547 218 (40%) 1 1
(+) 172 45 (26%) 0.53 (0.37-0.78) 0.86 (0.51-1.45)
MLH1*
(−) 632 250 (40%) 1 1
(+) 87 13 (15%) 0.27 (0.15-0.49) 0.68 (0.27-1.69)†
NEUROG1*
(−) 506 197 (39%) 1 1
(+) 213 66 (31%) 0.70 (0.50-0.99) 1.12 (0.74-1.70)
RUNX3*
(−) 575 227 (39%) 1 1
(+) 144 36 (25%) 0.51 (0.34-0.77) 0.98 (0.51-1.85)
SOCS1*
(−) 594 233 (39%) 1 1
(+) 125 30 (24%) 0.49 (0.31-0.76) 0.75 (0.44-1.28)
Other CpG islands
CHFR
(−) 410 154 (38%) 1 1
(+) 309 109 (35%) 0.91 (0.67-1.23) 1.19 (0.86-1.67)
HIC1
(−) 341 138 (40%) 1 1
(+) 378 125 (33%) 0.73 (0.54-0.99) 0.86 (0.63-1.19)
IGFBP3
(−) 525 191 (36%) 1 1
(+) 194 72 (37%) 1.03 (0.73-1.45) 1.31 (0.91-1.89)
MGMT
(−) 445 167 (38%) 1 1
(+) 274 96 (35%) 0.90 (0.66-1.23) 0.95 (0.69-1.31)
MINT1
(−) 464 178 (38%) 1 1
(+) 255 85 (33%) 0.80 (0.58-1.11) 1.05 (0.74-1.48)
MINT31
(−) 482 195 (40%) 1 1
(+) 237 68 (29%) 0.59 (0.42-0.83) 0.82 (0.55-1.23)
p14 (CDKN2A/ARF )
(−) 569 225 (40%) 1 1
(+) 150 38 (25%) 0.52 (0.35-0.78) 0.71 (0.45-1.12)
WRN
(−) 452 181 (40%) 1 1
(+) 267 82 (31%) 0.66 (0.48-0.91) 0.89 (0.62-1.28)
After adjusting for CIMP, all of the significant associations in the univariate analysis were
markedly attenuated.
*Eight markers in the CIMP-specific marker panel.
†Adjusted for CIMP and MSI because MLH1 methylation was associated with CIMP-high and
MSI-high, both of which could be confounders.
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with methylation in CACNA1G, CRABP1, IGF2,MLH1,NEUROG1,
RUNX3, SOCS1, HIC1, MINT31, p14, and WRN. However, after
adjusting for CIMP, all of these associations were markedly atten-
uated, and no association was considered to be highly significant,
given multiple hypotheses testing. These results suggest that none
of these 16 methylation markers were directly related with JCVT.
JC Virus T-Antigen Is Independently Associated with p53
Expression and CIN
We performed multivariate logistic regression analysis, to examine
which variables were independently associated with JCVT (Table 4).
JC virus T-antigen was significantly associated with p53 expression
(multivariate OR, 8.45; 95% CI, 5.72-12.5; P < .0001) and high
CIN score (multivariate OR, 2.53; 95% CI, 1.38-4.62; P = .003)
and inversely with high tumor grade (multivariate OR, 0.44; 95%
CI, 0.24-0.79; P = .006). JC virus T-antigen might also be associated
with cyclin D1 expression, LINE-1 hypomethylation, BRAFmutation,
and signet ring cells and inversely with family history of colorectal
cancer (all P values between 0.05 and 0.01); however, given multiple
hypotheses testing, any of these associations might be a chance event.
JC Virus T-Antigen and Patient Survival
We assessed the influence of JCVT expression on survival of pa-
tients with stage I to IV colorectal cancers. We have previously shown
that clinical outcome data in our two independent cohort studies are
valid and reliable to detect significant molecular predictors of patient
survival [44–46]. In the Kaplan-Meier analysis, JCVTexpression was
not significantly associated with patient survival (log-rank, P = .31
for colorectal cancer-specific mortality; log-rank, P = .67 for overall
mortality). We performed Cox regression analysis to assess mortalities
according to JCVT status (Table 5). For both cancer-specific and
overall mortalities, JCVT was not significantly related with patient
outcome in univariate analysis, stage-matched analysis, or multivari-
ate analysis. When we limited cases to only colon cancers, JCVT re-
mained unrelated with patient outcome. We examined whether JCVT
was associated with patient mortality in any of the strata of clinical or
molecular variables (such as age, sex, tumor stage, location, CIMP,
MSI, BRAF, LINE-1, etc.). However, there was no evidence for the
significant relation between JCVT and clinical outcome in any of
the strata, and there was no evidence for significant interaction between
JCVT and any of the variables in survival analysis (data not shown).
Discussion
We conducted this study to examine the relations of JCVTexpres-
sion with clinical, pathologic, and molecular characteristics and pa-
tient survival in colorectal cancers. Molecular correlates with JCVT
may be important for a better understanding of genetic and epige-
netic alterations during the colorectal carcinogenic process. We have
found that JCVT is independently associated with p53 expression
and CIN. In contrast, JCVT is inversely related with the CIMP
and MSI in univariate analysis but not in multivariate analysis. Our
data support the hypothesis that JCVT may affect p53 expression
and CIN rather than CIMP and MSI in colorectal cancer.
Studying molecular changes is important in cancer research [47–
64], and classification of colorectal cancer based on MSI and CIMP
is increasingly important because it reflects genomic and epigeno-
mic alterations, respectively, in tumor cells and largely determines
clinical, pathologic, and molecular characteristics [65]. To measure
DNA methylation, we used real-time PCR (MethyLight Technol-
ogy) for DNA methylation in eight CIMP-specific loci [33] as well
as in eight other CpG islands. We also used Pyrosequencing to mea-
Table 4. Multivariate Analysis of the Relations with JCVT in Colorectal Cancer.
Variable Independently Associated with JCVT Multivariate OR (95% CI) P
p53 expression 8.45 (5.72-12.5) <.0001
CIN score (≥2+ vs 0) 2.53 (1.38-4.62) .003
High tumor grade 0.44 (0.24-0.79) .006
Cyclin D1 expression 1.57 (1.08-2.27) .02
LINE-1 hypomethylation (30% decline as a unit) 1.97 (1.08-3.59) .03
BRAF mutation 2.20 (1.09-4.44) .03
Signet ring cells (present vs absent) 2.32 (1.05-5.16) .04
Family history of colorectal cancer 0.64 (0.42-0.98) .04
Multivariate logistic regression analysis assessing the relations with JCVT included age, sex, BMI, tumor location, stage, mucinous component, microsatellite instability, CIMP,
β-catenin, COX-2, p21, KRAS, PIK3CA, BRAF, and the variables listed in table. Only significant variables are listed.
Table 5. JC Virus T-Antigen Expression and Patient Mortality in Colorectal Cancer.
Total N Cancer-Specific Mortality Overall Mortality
Deaths/
Person-Years
Univariate HR
(95% CI)
Stage-Matched HR
(95% CI)
Multivariate HR
(95% CI)
Deaths/
Person-Years
Univariate HR
(95% CI)
Stage-Matched HR
(95% CI)
Multivariate HR
(95% CI)
Colon and rectum
JCVT (−) 446 (63%) 109/3658 1 (referent) 1 (referent) 1 (referent) 188/3658 1 (referent) 1 (referent) 1 (referent)
JCVT (+) 262 (37%) 73/2035 1.17 (0.87-1.57) 1.11 (0.82-1.51) 0.98 (0.69-1.40) 112/2035 1.05 (0.83-1.33) 1.05 (0.82-1.33) 0.94 (0.72-1.23)
Colon
JCVT (−) 361 (66%) 88/2977 1 (referent) 1 (referent) 1 (referent) 155/2977 1 (referent) 1 (referent) 1 (referent)
JCVT (+) 187 (34%) 49/1449 1.10 (0.78-1.56) 0.96 (0.67-1.38) 0.81 (0.52-1.26) 77/1449 1.00 (0.76-1.32) 1.05 (0.82-1.33) 0.84 (0.60-1.17)
The multivariate, stage-matched conditional Cox model included age, year of diagnosis, sex, BMI, family history of colorectal cancer, tumor location, stage, grade, KRAS, BRAF, PIK3CA, β-catenin,
COX-2, cyclin D1, p53, p21, LINE-1 methylation, microsatellite instability, and CIMP.
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sure LINE-1 methylation, which has been correlated well with cellu-
lar 5-methylcytosine level (i.e., genome-wide DNA methylation level)
[29,38,39]. Our resource of a large number of colorectal cancers derived
from the two prospective cohort studies has enabled us to precisely
estimate the frequency of colorectal cancers with a specific molecular
feature (such as JCVT expression, CIMP-high, p53 expression, etc.).
The large number of cases has also provided a sufficient power in our
multivariate logistic regression analysis and survival analysis.
Previous studies have reported the relationship of JC virus with
CIN and LOH [6,7]. Introduction of JC virus into a diploid cell line
can lead to CIN [7]. In addition, JCVT is strongly associated with
LOH in colorectal cancers [6]. In the current study, we have shown
that JCVT is associated with CIN and LINE-1 hypomethylation, in-
dependent of other variables. These data collectively support a pos-
sible role of JCVT in the development of CIN and genome-wide
DNA hypomethylation in colorectal cancers.
Regarding the relation between JCVT and p53, a previous study
has reported that JCVT can bind and inactivate both p53 and
phospho-RB proteins [11]. Especially, JCVT may affect other regu-
latory mechanisms for p53, which have been implicated in cancer
development [9]. Together with our current data of the independent
association between JCVT and p53 expression, accumulating data
suggest that JCVTmay dysregulate the p53 pathways, which can lead
to uncontrolled proliferation of colorectal cancer cells.
We have demonstrated that JCVT expression is associated with
p53 expression in colorectal cancer. One possible explanation for this
phenomenon is that there might be some cases with poor antigenicity
of JCVT and p53. Poor quality of tissue for immunohistochemistry
would have yielded a false-negative result in either the JCVT or p53
immunoassay, driving the overall relationship between JCVT and
p53 expression toward a concordant pattern. However, we have
shown that JCVT expression is inversely associated with p21 expres-
sion, which cannot be explained by the presence of poor-quality spe-
cimens. p21 has been known to be induced by wild-type p53, and
indeed, p53 expression (a surrogate of p53 mutation) was inversely
associated with p21 expression in our cohorts. These results imply
that the strong relation between JCVT and p53 expression we have
observed is not simply caused by the presence of poor-quality speci-
mens, leaving a possibility of a molecular interaction or other molec-
ular correlates between JCVT and p53. Interestingly, the relation
between JCVT and p21 loss did not persist after adjusting for p53,
suggesting that the link between JCVTand p21 loss was mediated by
p53 expression.
Previous studies have reported that methylation of host cell gene is
not unique to JC virus and occurs with other oncogenic viruses
[55,57,61,66]. Associations have been shown between methylation
of multiple genes and Epstein-Barr virus in gastric cancer [55,57]
and between promoter methylation and hepatitis B virus/hepatitis
C virus in hepatocellular cancer [61,66]. A significant association
has been found between the presence of SV40 T-antigen and meth-
ylation of multiple genes in non–Hodgkin lymphomas and mesothe-
liomas [67,68]. In addition, a previous study has reported that JCVT
may induce CIMP in colorectal cancers through multiple mecha-
nisms of epigenetic alterations [6]. However, our data do not support
the relation of JCVTwith CIMP (determined by the validated panel
of eight CIMP-specific promoters [24,33]) or methylation in any of
the 16 CpG islands we examined, using a large number of colorectal
cancers. We have shown an “inverse association” between JCVT and
CIMP in univariate analysis (P = .0005), which became insignificant
in multivariate analysis, indicating no independent association be-
tween JCVT and CIMP. In addition, none of the 16 CpG islands
seemed to be specifically related with JCVTafter adjusting for CIMP.
This discrepancy is likely caused by the differences in the sample sizes
(n = 100 in reference [6] vs n = 766 in our current study), the meth-
ylation markers examined (MLH1, APC, CDKN2A, p14, PTEN,
TIMP3, RUNX3, HIC1, and RARB in reference [6] vs CACNA1G,
CDKN2A,CRABP1, IGF2,MLH1,NEUROG1,RUNX3, SOCS1, and
eight other CpG islands in our current study), the methods to de-
tect DNA methylation (nonquantitative methylation-specific PCR
in reference [6] vs quantitative MethyLight in our current study)
and the criteria for methylator type or CIMP-high (no clear def-
inition in reference [6] vs the presence of ≥6 of 8 methylated
CIMP-specific promoters in our current study), and the statistical
methods (no multivariate analysis in reference [6] vs both multi-
variate and univariate analyses performed in our current study).
Considering that there is considerable heterogeneity of tumors with
regard to CpG island methylation and that CpG islands are meth-
ylated in a different manner, the difference in the methylation
markers between the two studies may explain discrepancies, at least
in part. However, some CpG islands (MLH1, RUNX3, CDKN2A,
p14, and HIC1) were used in both studies, and results on the same
markers seemed to be discordant. We have conducted rigorous sta-
tistical analysis for each marker and performed multivariate analysis
to assess independent associations and significant confounding. In
addition, we have comprehensively examined the relation between
JCVT and CIMP using the validated CIMP marker panel [24,33]
and a large number (n = 766) of colorectal cancers with robust sta-
tistics. Our results suggest that JCVT may not contribute to CIMP
in colorectal cancer. On the basis of our current results and data in
the literature, Figure 2 represents hypothetical relations with JCVT
in colorectal cancer.
In conclusion, using a large number of colorectal cancers, we have
shown that JCVT is independently associated with p53 expression
and CIN. Conversely, JCVT seems to be unrelated with CIMP, MSI,
or patient outcome. Our data suggest that JCVTmay contribute to
CIN and dysregulation of the p53 pathways, which may lead to un-
controlled proliferation of colorectal cancer cells.
Figure 2. Hypothetical relations with JCVT expression in colorectal
cancer. The thick lines with p53 and CIN imply the particularly tight
relations with JCVT. Data are based on this current study and ref-
erences [25,26,29,30,42].
Neoplasia Vol. 11, No. 1, 2009 JCV T-Antigen in Colorectal Cancer Nosho et al. 93
Acknowledgments
The authors thank the Nurses’ Health Study and Health Profes-
sionals Follow-up Study cohort participants who have generously
agreed to provide the biological specimens and information through
responses to questionnaires. The authors thank Frank Speizer, Walter
Willett, Susan Hankinson, Graham Colditz, Meir Stampfer, and
many other staff members who implemented and have maintained
the cohort studies.
No conflicts of interest exist.
References
[1] Shin SK, Li MS, Fuerst F, Hotchkiss E, Meyer R, Kim IT, Goel A, and Boland
CR (2006). Oncogenic T-antigen of JC virus is present frequently in human
gastric cancers. Cancer 107, 481–488.
[2] Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph
AE, and Boland CR (2000). JC virus DNA sequences are frequently present
in the human upper and lower gastrointestinal tract. Gastroenterology 119,
1228–1235.
[3] Krynska B, Del Valle L, Croul S, Gordon J, Katsetos CD, Carbone M, Giordano
A, and Khalili K (1999). Detection of human neurotropic JC virus DNA se-
quence and expression of the viral oncogenic protein in pediatric medullo-
blastomas. Proc Natl Acad Sci USA 96, 11519–11524.
[4] Del Valle L, Gordon J, Assimakopoulou M, Enam S, Geddes JF, Varakis JN,
Katsetos CD, Croul S, and Khalili K (2001). Detection of JC virus DNA se-
quences and expression of the viral regulatory protein T-antigen in tumors of the
central nervous system. Cancer Res 61, 4287–4293.
[5] Niv Y, Goel A, and Boland CR (2005). JC virus and colorectal cancer: a possible
trigger in the chromosomal instability pathways. Curr Opin Gastroenterol 21,
85–89.
[6] Goel A, Li MS, Nagasaka T, Shin SK, Fuerst F, Ricciardiello L, Wasserman L,
and Boland CR (2006). Association of JC virus T-antigen expression with the
methylator phenotype in sporadic colorectal cancers. Gastroenterology 130,
1950–1961.
[7] Ricciardiello L, Baglioni M, Giovannini C, Pariali M, Cenacchi G, Ripalti A,
Landini MP, Sawa H, Nagashima K, Frisque RJ, et al. (2003). Induction of
chromosomal instability in colonic cells by the human polyomavirus JC virus.
Cancer Res 63, 7256–7262.
[8] Gan DD and Khalili K (2004). Interaction between JCV large T-antigen and
beta-catenin. Oncogene 23, 483–490.
[9] Enam S, Del Valle L, Lara C, Gan DD, Ortiz-Hidalgo C, Palazzo JP, and Khalili
K (2002). Association of human polyomavirus JCV with colon cancer: evidence
for interaction of viral T-antigen and beta-catenin. Cancer Res 62, 7093–7101.
[10] Shimazu T, Komatsu Y, Nakayama KI, Fukazawa H, Horinouchi S, and Yoshida
M (2006). Regulation of SV40 large T-antigen stability by reversible acetylation.
Oncogene 25, 7391–7400.
[11] Ludlow JW (1993). Interactions between SV40 large-tumor antigen and the
growth suppressor proteins pRB and p53. FASEB J 7, 866–871.
[12] Enam S, Gan DD, White MK, Del Valle L, and Khalili K (2006). Regulation of
human neurotropic JCV in colon cancer cells. Anticancer Res 26, 833–841.
[13] Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, and Issa JP
(1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad
Sci USA 96, 8681–8686.
[14] Issa JP, Shen L, and Toyota M (2005). CIMP, at last. Gastroenterology 129,
1121–1124.
[15] Grady WM (2007). CIMP and colon cancer gets more complicated. Gut 56,
1498–1500.
[16] Teodoridis JM, Hardie C, and Brown R (2008). CpG island methylator pheno-
type (CIMP) in cancer: causes and implications. Cancer Lett 268, 177–186.
[17] Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N,
Young J, Meltzer SJ, Leggett BA, and Jass JR (2002). Morphological and
molecular heterogeneity within nonmicrosatellite instability–high colorectal
cancer. Cancer Res 62, 6011–6014.
[18] Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O’Connor T,
and Ward R (2002). CpG island methylation in sporadic colorectal cancers and
its relationship to microsatellite instability. Gastroenterology 122, 1376–1387.
[19] van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, and Iacopetta B (2002). Char-
acterisation of colorectal cancers showing hypermethylation at multiple CpG
islands. Gut 51, 797–802.
[20] Kambara T, Simms LA, Whitehall VLJ, Spring KJ, Wynter CVA, Walsh MD,
Barker MA, Arnold S, McGivern A, Matsubara N, et al. (2004). BRAF mutation
is associated with DNA methylation in serrated polyps and cancers of the colo-
rectum. Gut 53, 1137–1144.
[21] Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K,
Kambara T, MacPhee DG, Young J, Leggett BA, et al. (2004). Colorectal cancer
with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes
showing different patterns of DNA methylation. J Clin Oncol 22, 4584–4594.
[22] Samowitz W, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA,
Wolff RK, and Slattery ML (2005). Evaluation of a large, population-based sam-
ple supports a CpG island methylator phenotype in colon cancer. Gastroenter-
ology 129, 837–845.
[23] Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger
DJ, Campan M, Laird PW, Loda M, and Fuchs CS (2006). CpG island methyl-
ator phenotype (CIMP) of colorectal cancer is best characterised by quantitative
DNA methylation analysis and prospective cohort studies. Gut 55, 1000–1006.
[24] Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA,
Kang GH, Widschwendter M, Weener D, Buchanan D, et al. (2006). CpG
island methylator phenotype underlies sporadic microsatellite instability and
is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38,
787–793.
[25] Kawasaki T,Nosho K,OhnishiM, Suemoto Y, Kirkner GJ, Dehari R,Meyerhardt
JA, Fuchs CS, and Ogino S (2007). Correlation of beta-catenin localization with
cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in
colorectal cancer. Neoplasia 9, 569–577.
[26] Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton
C, Mayer RJ, Goldberg R, Bertagnolli MM, et al. (2007). The CpG island meth-
ylator phenotype and chromosomal instability are inversely correlated in sporadic
colorectal cancer. Gastroenterology 132, 127–138.
[27] Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, and Albertsen H
(2007). APC mutations and other genetic and epigenetic changes in colon can-
cer. Mol Cancer Res 5, 165–170.
[28] Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G,
and Kawakami K (2006). APC gene methylation is inversely correlated with
features of the CpG island methylator phenotype in colorectal cancer. Int J Can-
cer 119, 2272–2278.
[29] Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, and Fuchs
CS (2008). LINE-1 hypomethylation is inversely associated with microsatellite
instability and CpG island methylator phenotype in colorectal cancer. Int J Can-
cer 122, 2767–2773.
[30] Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, and Fuchs CS (2007). 18q loss
of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG
island methylator phenotype–negative (CIMP-0) and inversely with CIMP-low
and CIMP-high. BMC Cancer 7, 72.
[31] Colditz GA and Hankinson SE (2005). The Nurses’ Health Study: lifestyle and
health among women. Nat Rev Cancer 5, 388–396.
[32] Chan AT, Ogino S, and Fuchs CS (2007). Aspirin and the risk of colorectal
cancer in relation to the expression of COX-2. N Engl J Med 356, 2131–2142.
[33] Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, and Fuchs CS (2007).
Evaluation of markers for CpG island methylator phenotype (CIMP) in colo-
rectal cancer by a large population-based sample. J Mol Diagn 9, 305–314.
[34] Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L,
Longtine JA, Fuchs CS, and Ogino S (2008). PIK3CAmutation in colorectal can-
cer: relationship with genetic and epigenetic alterations. Neoplasia 10, 534–541.
[35] Eads CA,Danenberg KD, Kawakami K, Saltz LB, BlakeC, ShibataD,Danenberg
PV, and Laird PW (2000). MethyLight: a high-throughput assay to measure
DNA methylation. Nucleic Acids Res 28, E32.
[36] Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D,
Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, et al. (2006). Pre-
cision and performance characteristics of bisulfite conversion and real-time
PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8,
209–217.
[37] Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, and
Ogino S (2007). IGFBP3 promoter methylation in colorectal cancer: relation-
ship with microsatellite instability, CpG island methylator phenotype, and p53.
Neoplasia 9, 1091–1098.
[38] Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang
AS, Yan PS, Huang TH, et al. (2007). LINE-1 hypomethylation in cancer is
highly variable and inversely correlated with microsatellite instability. PLoS ONE
2, e399.
94 JCV T-Antigen in Colorectal Cancer Nosho et al. Neoplasia Vol. 11, No. 1, 2009
[39] Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, and Issa JP (2004). A
simple method for estimating global DNA methylation using bisulfite PCR of
repetitive DNA elements. Nucleic Acids Res 32, e38.
[40] Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, and Fuchs CS (2007).
Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with
microsatellite instability and CIMP. Mod Pathol 20, 15–22.
[41] Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C,
Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, et al. (2005). Molecular
alterations in tumors and response to combination chemotherapy with gefitinib
for advanced colorectal cancer. Clin Cancer Res 11, 6650–6656.
[42] Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, and Fuchs
CS (2006). Down-regulation of p21 (CDKN1A/CIP1) is inversely associated
with microsatellite instability and CpG island methylator phenotype (CIMP)
in colorectal cancer. J Pathol 210, 147–154.
[43] Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs
CS, and Ogino S (2008). Cyclin D1 is frequently overexpressed in microsatellite
unstable colorectal cancer, independent of CpG island methylator phenotype.His-
topathology 53, 588–598.
[44] Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES,
Giovannucci EL, and Fuchs CS (in press). A cohort study of tumoral LINE-1
hypomethylation and prognosis in colon cancer. J Natl Cancer Inst.
[45] Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman
JA, Kraft P, Cantley LC, et al. (in press). PIK3CAmutation is associated with poor
prognosis among patients with curatively resected colon cancer. J Clin Oncol.
[46] Ogino S, Nosho K, Kirkner GJ, Kawasaki T,Meyerhardt JA, LodaM,Giovannucci
EL, and Fuchs CS (in press). CpG island methylator phenotype, microsatellite
instability, BRAFmutation and clinical outcome in colon cancer. Gut. (published
online on 2 Oct 2008. doi:2010.1136/Gut2008.155473).
[47] Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T, Langley RR, Fan
D, Kim SJ, and Fidler IJ (2007). Inhibition of epidermal growth factor recep-
tor and vascular endothelial growth factor receptor phosphorylation on tumor-
associated endothelial cells leads to treatment of orthotopic human colon cancer
in nude mice. Neoplasia 9, 1066–1077.
[48] Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR,
Judson IR, Workman P, Leach MO, et al. (2008). Noninvasive magnetic reso-
nance spectroscopic pharmacodynamic markers of a novel histone deacetylase in-
hibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 10,
303–313.
[49] Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE,
Dallapiccola B, and Lothe RA (2008). RAS signaling in colorectal carcino-
mas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 10,
680–686.
[50] Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG,
Weijenberg MP, de Bruine AP, Meijer GA, and van Engeland M (2008). Inte-
grated analysis of chromosomal, microsatellite and epigenetic instability in colo-
rectal cancer identifies specific associations between promoter methylation of
pivotal tumour suppressor and DNA repair genes and specific chromosomal al-
terations. Carcinogenesis 29, 434–439.
[51] Derouet M, Wu X, May L, Hoon Yoo B, Sasazuki T, Shirasawa S, Rak J, and
Rosen KV (2007). Acquisition of anoikis resistance promotes the emergence of
oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumor-
igenicity in vivo. Neoplasia 9, 536–545.
[52] Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R,
and Hinoda Y (2008). Frizzled-7 as a potential therapeutic target in colorectal
cancer. Neoplasia 10, 697–705.
[53] Henkhaus RS, RoyUK, Cavallo-MedvedD, Sloane BF, Gerner EW, and Ignatenko
NA (2008). Caveolin-1–mediated expression and secretion of kallikrein 6 in
colon cancer cells. Neoplasia 10, 140–148.
[54] Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schutz A, Kovacic B,
and Friedrich K (2007). Signal transducer and activator of transcription 3 acti-
vation promotes invasive growth of colon carcinomas through matrix metallo-
proteinase induction. Neoplasia 9, 279–291.
[55] Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, and Ro JY (2002).
Epstein-Barr virus–positive gastric carcinoma demonstrates frequent aberrant
methylation of multiple genes and constitutes CpG island methylator pheno-
type–positive gastric carcinoma. Am J Pathol 160, 787–794.
[56] Cengel KA, Voong KR, Chandrasekaran S,Maggiorella L, Brunner TB, Stanbridge
E, Kao GD, McKenna WG, and Bernhard EJ (2007). Oncogenic K-Ras signals
through epidermal growth factor receptor andwild-typeH-Ras to promote radiation
survival in pancreatic and colorectal carcinoma cells. Neoplasia 9, 341–348.
[57] Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M,
Shinomura Y, Imai K, and Tokino T (2006). Genetic, epigenetic, and clinico-
pathologic features of gastric carcinomas with the CpG island methylator pheno-
type and an association with Epstein-Barr virus. Cancer 106, 1467–1479.
[58] Rocken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J, Jacobi
CA, Kalmuk S, Neuhaus P, and Neumann U (2007). The gene polymorphism
of the angiotensin I–converting enzyme correlates with tumor size and patient
survival in colorectal cancer patients. Neoplasia 9, 716–722.
[59] Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX,
and Fang JY (2008). Inhibition of JAK1, 2/STAT3 signaling induces apoptosis,
cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neo-
plasia 10, 287–297.
[60] Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D’Almeida V,
Correa M, and Jasiulionis MG (2007). Oxidative stress modulates DNA meth-
ylation during melanocyte anchorage blockade associated with malignant trans-
formation. Neoplasia 9, 1111–1121.
[61] Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, and Wei L (2008).
CpG island methylator phenotype association with upregulated telomerase ac-
tivity in hepatocellular carcinoma. Int J Cancer 123, 998–1004.
[62] Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA, Greenhough A,
Dallosso AR, Huang TH, Royer-Pokora B, Brown KW, et al. (2007). Hypo-
methylation and aberrant expression of the glioma pathogenesis–related 1 gene
in Wilms tumors. Neoplasia 9, 970–978.
[63] Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M,
Malfertheiner P, Lippert H, Roessner A, et al. (2007). Early involvement of
death-associated protein kinase promoter hypermethylation in the carcinogene-
sis of Barrett’s esophageal adenocarcinoma and its association with clinical pro-
gression. Neoplasia 9, 236–245.
[64] Litkouhi B, Kwong J, Lo CM, Smedley JG III, McClane BA, Aponte M, Gao
Z, Sarno JL, Hinners J, Welch WR, et al. (2007). Claudin-4 overexpression in
epithelial ovarian cancer is associated with hypomethylation and is a potential
target for modulation of tight junction barrier function using a C-terminal frag-
ment of Clostridium perfringens enterotoxin. Neoplasia 9, 304–314.
[65] Ogino S and Goel A (2008). Molecular classification and correlates in colorectal
cancer. J Mol Diagn 10, 13–27.
[66] Yang B, Guo M, Herman JG, and Clark DP (2003). Aberrant promoter meth-
ylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J
Pathol 163, 1101–1107.
[67] Suzuki M, Toyooka S, Shivapurkar N, Shigematsu H, Miyajima K, Takahashi T,
Stastny V, Zern AL, Fujisawa T, Pass HI, et al. (2005). Aberrant methylation
profile of human malignant mesotheliomas and its relationship to SV40 infec-
tion. Oncogene 24, 1302–1308.
[68] Shivapurkar N, Takahashi T, Reddy J, Zheng Y, Stastny V, Collins R, Toyooka S,
Suzuki M, Parikh G, Asplund S, et al. (2004). Presence of simian virus 40 DNA se-
quences in human lymphoid and hematopoietic malignancies and their relationship
to aberrant promoter methylation of multiple genes. Cancer Res 64, 3757–3760.
Neoplasia Vol. 11, No. 1, 2009 JCV T-Antigen in Colorectal Cancer Nosho et al. 95
